Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies with aprindine.

D P Zipes, V Elharrar, R F Gilmour

    American Heart Journal
    |December 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations].

    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2002
    Same author

    What's bad for the gander...women and sudden cardiac death.

    Heart (British Cardiac Society)·2002
    Same author

    Task Force on Sudden Cardiac Death, European Society of Cardiology.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2002
    Same author

    President's page: guidelines: tools for building better patient care.

    Journal of the American College of Cardiology·2001
    Same author

    Saving time saves lives.

    Circulation·2001
    Same author

    President's page: quality of care: a moving target worthy of pursuit.

    Journal of the American College of Cardiology·2001
    Same journal

    Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

    American heart journal·2026
    Same journal

    Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

    American heart journal·2026
    Same journal

    Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

    American heart journal·2026
    Same journal

    Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

    American heart journal·2026
    Same journal

    THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

    American heart journal·2026
    Same journal

    DOAC Score Among Patients Receiving Vitamin K Antagonists.

    American heart journal·2026
    See all related articles

    Aprindine effectively treats supraventricular and ventricular tachyarrhythmias by slowing cardiac conduction. However, its narrow therapeutic-toxic ratio means its effect on arrhythmias can vary, even causing them in some situations.

    Area of Science:

    • Pharmacology and Cardiology
    • Cardiac Electrophysiology

    Background:

    • Aprindine is a potent antiarrhythmic drug.
    • It exhibits a narrow therapeutic-toxic ratio, requiring careful dosage.
    • Effective in managing supraventricular and ventricular tachyarrhythmias.

    Purpose of the Study:

    • To investigate the electrophysiological effects of aprindine.
    • To understand its mechanism in suppressing cardiac arrhythmias.
    • To evaluate its arrhythmogenic potential in a canine model.

    Main Methods:

    • Utilized voltage-clamp studies on frog atria.
    • Administered aprindine to dogs undergoing coronary artery occlusion.
    • Assessed the temporal relationship between drug administration and induced arrhythmias.

    Related Experiment Videos

    Main Results:

    • Aprindine slows conduction in all cardiac fibers.
    • Higher doses suppress slow inward currents in frog atria.
    • In dogs, aprindine's effect (antiarrhythmic, arrhythmogenic, or none) depends on administration timing relative to occlusion.

    Conclusions:

    • Aprindine is a potent antiarrhythmic agent with complex electrophysiological actions.
    • Its clinical use requires careful consideration of its narrow therapeutic index.
    • The drug's arrhythmogenic potential in ischemic conditions necessitates further investigation into timing-dependent effects.